TP53 and ovarian carcinoma: Importantly, DNMTis sensitize TP53-mutant ovarian cancer cells—present in over 90% of high-grade serous ovarian carcinomas to IFN responses, amplifying anti-tumor immunity across diverse TP53 mutational statuses.